Development of a Peptide-based Universal Influenza Vaccine

This study aims to develop a safe and effective peptide-based universal influenza vaccine targeting dendritic cells, that stimulates cell mediated immunity to reduce morbidity and mortality associated with influenza virus infection. Such a vaccine can be made in advance of a pandemic and can also support seasonal vaccines particularly when they fail to adequately match circulating strains. The results of this project can therefore contribute to national (and international) preparedness for an eventual inf luenza pandemic. The study will involve detailed analysis of genomic sequences available in public databases to identify regions conserved between influenza viruses infecting human, avian and mammalian species. Protein fragments (peptides) corresponding t o conserved domains will be modified to enhance their ability to stimulate the human immune system using a proprietary technology (Partner 1:Bionor Immuno). An innovative cell system will be used to determine the ability of these modified peptides to indu ce the production of immune cells that can seek out and kill cells expressing influenza virus in culture (Partner 2:St Georges Hospital Medical School, UK). The effect of peptide immunisation on infection rates and clinical illness will be determined in a murine model for influenza. Since the peptides are designed to match the human immune system, transgenic mice expressing human immunological markers (HLA) will also be analysed in parallel. Effective peptides will undergo toxicology testing to Good Labor atory Practice (GLP) as well as clinical/pharmaceutical development including stability testing of the candidate in a liquid form (Partner 3:Norwegian Institute of Public Health). This study supports FUGE`s plan of action (2005-2008) where analysis of mu ltiple genomic sequences is used to provide the basis for new products that have the potential to support healthcare services and prepare against global infections.